FINWIRES · TerminalLIVE
FINWIRES

HC Wainwright Downgrades Crescent Biopharma to Neutral From Buy

By

Crescent Biopharma (CBIO) has an average rating of buy and mean price target of $29.50, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Loop Capital Initiates Carnival at Buy With $36 Price Target

Carnival (CCL) has an average rating of buy and mean price target of $34.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CCL
Research

TD Cowen Downgrades Cardiff Oncology to Hold From Buy

Cardiff Oncology (CRDF) has an average rating of overweight and mean price target of $8.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CRDF
Research

Deutsche Bank Downgrades Caesars Entertainment to Hold From Buy, Lowers Price Target to $31 From $35

Caesars Entertainment (CZR) has an average rating of overweight and mean price target of $31.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CZR